An immunometabolic prodrug strategy overcomes DHODH inhibitor resistance in refractory melanoma
Abstract Background Metabolic reprogramming, particularly upregulated de novo pyrimidine biosynthesis, drives cancer progression and immune evasion. Dihydroorotate dehydrogenase (DHODH), a key enzyme in this pathway, is a promising therapeutic target, but its inhibitors often face resistance in immu...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2025-11-01
|
| Col·lecció: | Journal of Experimental & Clinical Cancer Research |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s13046-025-03566-6 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|